THZ2 is a potent and selective CDK7 inhibitor with an IC50 of 13.9 nM.
IC50&Target
CDK7
13.9 nM (IC50)
CDK1
96.9 nM (IC50)
CDK2
222 nM (IC50)
CDK5
134 nM (IC50)
CDK9
194 nM (IC50)
CDK8
6830 nM (IC50)
体外研究
THZ2 selectively targets CDK7 and potently inhibits the growth of triple-negative but not ER/PR breast cancer cells. THZ2 at low nanomolar doses also efficiently suppresses the clonogenic growth of TNBC cells with IC50 of appr 10 nM. THZ2 induces apoptotic cell death in triple-negative but not ER/PR breast cancer cells or normal human cells.
体内研究
THZ2 (10 mg/Kg) markedly reduces the growth rate of tumors in mice and demonstrates an anti-tumor activity. Compared to vehicle-treated tumors, tumor tissues isolated from mice treated with THZ2 has reduced proliferation and increased apoptosis, as indicated by immunostaining against Ki67 and cleaved Caspase 3 respectively. THZ2 in NOD-SCID mice leads to reduced body weight, suggesting that THZ2 mayt be less well-tolerated in this particular mouse strain.
分子式
C31H28ClN7O2
分子量
566.05
CAS号
1604810-84-5
运输条件
Room temperature in continental US; may vary elsewhere.